# Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

> **NCT06862739** · PHASE4 · RECRUITING · sponsor: **Nabiqasim Industries (Pvt) Ltd** · enrollment: 800 (estimated)

## Conditions studied

- Diabetes Mellitus
- Type 2 DM

## Interventions

- **COMBINATION_PRODUCT:** Empagliflozin+Linagliptin+Metformin

## Key facts

- **NCT ID:** NCT06862739
- **Lead sponsor:** Nabiqasim Industries (Pvt) Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-30
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06862739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06862739, "Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT06862739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*